The U.S. central venous catheter market involves medical devices that are inserted into a central vein to administer medications or fluids, withdraw blood samples, and measure central venous pressure. Central venous catheters are crucial for critically ill patients who need longer term IV access or treatment. They are widely utilized in intensive care units and emergency departments for administering chemotherapy and total parenteral nutrition. The increasing prevalence of chronic diseases such as cancer and rising number of ICU admissions has boosted the demand for central venous catheters in the country.

The U.S. central venous catheter market is estimated to be valued at US$ 1252.07 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period of 2024 to 2031.

Key Takeaways

Key players operating in The U.S. Central Venous Catheter are Robert Bosch GmbH., Continental AG, DENSO CORPORATION, HELLA GmbH & Co. KGaA, Infineon Technologies AG, Autoliv Inc., Lockheed Martin Corporation., NXP Semiconductors., smart microwave sensors GmbH, Oculii Corporation, SRC, Inc., Arbe, Echodyne Corp., Raytheon Company Corporation, Saab AB, Northrop Grumman, ZF Friedrichshafen AG, Hitachi, Ltd., InnoSenT - Innovative Radar Sensor Technology, and Kestrel Radar Sensors among others. The U.S accounts for over 40% market share in North America.

The growing geriatric population suffering from chronic diseases provides lucrative growth opportunities. Additionally, technological advancements in catheter design and rising investments in critical care units are expected to drive the market. Catheter manufacturers are focusing on expanding their global footprint especially in emerging Asian markets.

Market drivers and restrain

The increasing incidence of lifestyle diseases and growing prevalence of cancer are key factors driving the demand for central venous catheters. According to the Center for Disease Control and Prevention, around 600,000 people in the U.S. suffer a heart attack each year out of which around 300,000 patients need central line placement in ICUs.

However, risks associated with central line-associated bloodstream infections can negatively impact the market growth. Maintaining aseptic placement techniques and adherence to guidelines for catheter care are important to reduce such risks. Catheter fracture or embolization during placement is another challenge. Stringent regulations requiring clinical trials for new product approvals also restrain market growth to some extent.

Segment Analysis
The U.S. Central Venous Catheter market is dominated by peripherally inserted central catheters(PICC) segment which holds around 40% share. PICC segment is dominating as these catheters have reduced risk of infection and thrombosis, provide reliable long term venous access and are more comfortable for patients as these can be placed at bedside under ultrasound guidance without any surgical procedure.

Global Analysis
The North America region dominated the U.S. Central Venous Catheter market in 2024 with a share of around 60%. The high market share of the North America region is attributed to the rising incidences of chronic diseases like cancer requiring chemotherapy, the presence of advanced healthcare facilities and increasing adoption of innovative central vascular access devices. Asia Pacific is expected to witness the fastest growth during the forecast period owing to growing healthcare expenditure, rising medical tourism, increasing surgical procedures and improving healthcare infrastructure in emerging economies of China and India.

Get more insights on U.S. Central Venous Catheter Market